Feasibility of Mynxgrip®-Assisted Percutaneous Transhepatic Portal Venous Access Closure

Purpose Life-threatening bleeding may occur following percutaneous portal venous access procedures. Various embolic agents have been utilised to minimise this risk, each with their own disadvantages, including inadvertent embolization of the portal vein and inadequate tract embolization. We aim to assess the feasibility of a novel approach to percutaneous portal venous access closure by utilising the MYNXGRIP (R) vascular closure device (Cardinal Health, USA). Materials and Methods This retrospective study analysed 20 patients who underwent interventional radiological procedures with closure of the percutaneous transhepatic portal venous access tract using the MYNXGRIP (R) closure device with either N-butyl cyanoacrylate or thick gelatin paste. Results None of these patients demonstrated clinical evidence of post-procedural haemorrhage, which was further confirmed on abdominal imaging in 15 of these patients. Conclusion MYNXGRIP (R)-assisted percutaneous transhepatic portal venous access closure is feasible and able to achieve haemostasis with minimal embolization risk.